Fractyl Health Investors Face October Deadline in Securities Lawsuit

The legal complaint alleges that Fractyl Health misled shareholders regarding the effectiveness of its Revita procedure. According to the suit, the company failed to disclose that operational issues at REMAIN-1 clinical trial sites compromised the integrity of efficacy data. These omissions allegedly led to inflated expectations for the company’s regulatory and commercial prospects.

Investors who purchased GUTS shares during the specified period may contact the Law Offices of Frank R. Cruz to review their legal rights. Participation in the class action does not require immediate action, as individuals may choose to retain their own counsel or remain passive members of the class.